Congenica

Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers to provide life-changing answers that will in future improve wellbeing and disease management.

Congenica offers the world’s leading clinical decision support platform for accelerated genomic data interpretation.

Congenica was founded in 2014 and is headquartered in Cambridge, Cambridgeshire, United Kingdom.

Congenica's scalable software for end-to-end genomic analysis empowers you to interpret next-generation sequencing data in as little as 5-minutes, guide treatment decisions and transform people’s lives.

Congenica's platform maximizes your efficiency, analytical yield and confidence in every case, rapidly transforming data into actionable insights to improve outcomes.

 

Congenica converts genomic data into actionable information, expediting the process through more efficient and accurate analysis. This supports healthcare professionals in providing patients with robust diagnoses and precise, personalised care.

 

Congenica is backed by Tencent, Parkwalk Advisors, Cambridge Innovation Capital, Downing, Legal & General, Xeraya, Puhua Capital, IDO Investments and others. The company raised $50M (£39M) in Series C round on Nov 09, 2020. This brings Congenica's total funding to £63.7M to date.

 

 

  • Year founded: 2014
  • Funding Info: £63.7M over 5 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Cambridgeshire
  • Country: United Kingdom
Related businesses